Clinical trials: Neuroepithelial Tumor
Adult Glioblastoma
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Glioblastomas are extremely resistant to treatment, including radiotherapy and/or chemotherapy. Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation…
- Trial name
- GLYRad (NCT02364206)
- Testing
- LY2228820, Temozolomide, radiotherapy
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Jean Perrin
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent…
- Trial name
- NCT00003304
- Testing
- temozolomide
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 29 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Primary Malignant Neoplasm of Nervous System, Glioma
Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery
The investigators hypothesize that the rate of radiologically complete resections of contrast-enhancing brain tumors following surgeries aided by use of 5-ALA induced fluorescence guidance and use of an intraoperative ultra-low…
- Conditions
- Primary Malignant Neoplasm of Nervous System, Glioma, Glioblastoma, Metastasis
- Trial name
- IMAGER (NCT01798771)
- Testing
- Interventional arm, Control arm
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Glioblastoma
Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients
This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma.
- Trial name
- NCT07775534
- Testing
- Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Glioblastoma
89Zr-RO5323441 PET Imaging in Glioblastoma
The research the investigators propose is a molecular imaging study of RO5323441, an antibody against placental growth factor (PlGF) in patients with recurrent GBM treated with bevacizumab, a drug against vascular endothelial…
- Trial name
- NCT01622764
- Testing
- Molecular imaging with 89Zr-RO5323441
- Where
- Netherlands
- Sponsor
- University Medical Center Groningen
Glioblastoma (GBM)
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis.
- Trial name
- Andro-iGlio (NCT07472387)
- Testing
- blood sampling, saliva sampling, stool sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Astrocytoma
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
- Trial name
- NCT03032484
- Testing
- Bevacizumab, TVB-2640
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioblastoma (GBM)
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients.
- Trial name
- NCT07130149
- Testing
- Sonodynamic Therapy (SDT), Standard Treatment
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Yingjuan Zheng
Glioblastoma
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted…
- Trial name
- PRIDE (NCT05871021)
- Testing
- Dose escalation of radiation dose beyond the therapeutic standard
- Where
- 9 sites in Germany
- Volunteers
- 107 people
- Sponsor
- University Hospital Tuebingen
Osteosarcoma, Ewing Sarcoma
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor
- Trial name
- NCT05302921
- Testing
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's National Research Institute
Recurrent Medulloblastoma
RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)
- Trial name
- PNOC020 rMB (NCT07492316)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Glioma
Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated.
- Trial name
- NCT03193463
- Testing
- Topotecan (<=8cc), Topotecan (>8cc), Cleveland Multiport Catheter
- Sponsor
- Michael Vogelbaum, MD, PhD
Malignant Glioma, Glioblastoma Multiforme
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL13-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00041587
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma
Bioenergetic Profiling and Cognition in GBM Patients
This trial studies the use of blood-based bioenergetic profiling and cognitive testing in assessing patients with glioblastoma undergoing chemoradiation therapy.
- Trial name
- NCT03939858
- Testing
- Cognitive Assessment, Blood Collection, Bioenergetic Profiling
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Glioma, Anaplastic Astrocytoma
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT03072134
- Testing
- Neural stem cells loaded with an oncolytic adenovirus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV)
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways…
- Conditions
- High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma
- Trial name
- NCT07206849
- Testing
- Tovorafenib
- Volunteers
- 79 people
- Sponsor
- Nationwide Children's Hospital
Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
- Conditions
- Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain, Gliosarcoma of Brain, Anaplastic Astrocytoma of Brain
- Trial name
- NCT06193174
- Testing
- C134 Re-Administration
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma
Expectations and Needs of a Glioblastoma Caregiver
Cancers of the central nervous system have a poor prognosis. Glioblastoma is most common glial tumor of the central nervous system.
- Trial name
- GLOIOS (NCT06490497)
- Testing
- Interview
- Where
- France
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Hopital Nord Franche-Comte
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.